Markers of early disease and prognosis in COPD

International Journal of COPD

Volumn 4, Issue 1, 2009, Pages 157-167

  Dahl, Morten ^a   Nordestgaard, Børge G ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Blomarker; Chronic obstructive pulmonary disease; Genetics; Pathogenesis; Prognosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; FIBRINOGEN; MANNOSE BINDING LECTIN 2; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADAPTIVE IMMUNITY; AIRWAY OBSTRUCTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVITY; FIBRINOGEN BLOOD LEVEL; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; INNATE IMMUNITY; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PREDICTION; PROGNOSIS; PROTEIN DETERMINATION; RISK ASSESSMENT; RISK FACTOR;

ALPHA 1-ANTITRYPSIN DEFICIENCY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DENMARK; EARLY DIAGNOSIS; FIBRINOGEN; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HOSPITALIZATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MANNOSE-BINDING LECTIN; ODDS RATIO; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 66149093897     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-1276.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
3. Dahl M, Bauer AK, Arredouani M, et al. Protection against inhaled oxidants through scavenging of oxidized lipids by macrophage receptors MARCO and SR-AI/II. J Clin Invest. 2007;117:757-764.
4. Owen CA. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3:253-268.
5. Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. J Clin Invest. 2008;118:394-402.
6. Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev. 2007;87:1047-1082.
7. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416-469.
8. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:822-832.
9. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008;31:869-873.
10. Epidemiology of chest pain and angina pectoris, with special reference to treatment needs. Acta Med Scand Suppl. 1984;682:1-120.
11. The Copenhagen City Heart Study. Osterbroundersogelsen. A book of tables with data from the first examination (1976-78) and a five year follow-up (1981-83). The Copenhagen City Heart Study Group. Scand J Soc Med Suppl. 1989;41:1-160.
12. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study - Østerbroundersøgelsen. Tables with data from the third examination 1991-1994. Eur Heart J Suppl. 2001; 3:H1-H83.
13. Garcia-Laorden MI, Sole-Violan J, Rodriguez DC, et al. Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J Allergy Clin Immunol. 2008;122:368-74, 374.
14. Yang IA, Seeney SL, Wolter JM, et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun. 2003;4:269-274.
15. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-580.
16. Olafsdottir IS, Gislason T, Thjodleifsson B, et al. Gender differences in the association between C-reactive protein, lung function impairment, and COPD. Int J Chron Obstruct Pulmon Dis. 2007;2:635-642.
17. Gooptu B, Lomas DA. Polymers and inflammation: disease mechanisms of the serpinopathies. J Exp Med. 2008;205:1529-1534.
18. Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. Ann Intern Med. 2002;136:270-279.
19. Dahl M, Nordestgaard BG, Lange P, Vestbo J, Tybjaerg-Hansen A. Molecular diagnosis of intermediate and severe alpha(1)-antitrypsin deficiency: MZ individuals with chronic obstructive pulmonary disease may have lower lung function than MM individuals. Clin Chem. 201;47:56-62.
20. Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK, Nordestgaard BG. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J. 2005;26:67-76.
21. Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax. 2004;59:843-849.
22. Dahl M, Nordestgaard BG, Tybjörg-Hansen A. Molecular diagnosis of intermediate and severe alpha1-antitrypsin deficiency by use of multiplex polymerase chain reaction. In: Bruns DE, Lo YMD, Wittwer CT, eds. Molecular testing in laboratory medicine. Washington DC: AACC Press; 2002. p. 250-258.
23. Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG. DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet. 1998;351:1911-1913.
24. Dahl M, Nordestgaard BG, Lange P, Tybjaerg-Hansen A. Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fibrosis phenylalanine-508 deletion. J Allergy Clin Immunol. 2001;107:818-823.
25. Dahl M, Tybjaerg-Hansen A, Wittrup HH, Lange P, Nordestgaard BG. Cystic fibrosis Delta F508 heterozygotes, smoking, and reproduction: studies of 9141 individuals from a general population sample. Genomics. 1998;50:89-96.
26. Estivill X, Bancells C, Ramos C. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat. 1997; 10:135-154.
27. Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG. Asthma and COPD in cystic fibrosis intron-8 5T carriers. A population-based study. Respir Res. 2005;6:113.
28. Delaney SJ, Rich DP, Thomson SA, et al. Cystic fibrosis transmembrane conductance regulator splice variants are not conserved and fail to produce chloride channels. Nat Genet. 1993;4:426-431.
29. Castellani C, Quinzii C, Altieri S, Mastella G, Assael BM. A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. Genet Test. 2001;5:249-254.
30. Conneally PM, Merritt AD, Yu PL. Cystic fibrosis: population genetics. Tex Rep Biol Med. 1973;31:639-650.
31. de Cid R, Chomel JC, Lazaro C, et al. CFTR and asthma in the French EGEA study. Eur J Hum Genet. 2001;9:67-69.
32. Griesenbach U, Geddes DM, Alton EW. The pathogenic consequences of a single mutated CFTR gene. Thorax. 1999;54 Suppl 2:S19-S23.
33. Hoffjan S, Nicolae D, Ober C. Association studies for asthma and atopic diseases: a comprehensive review of the literature. Respir Res. 2003;4:14.
34. Lazaro C, de Cid R, Sunyer J, et al. Missense mutations in the cystic fibrosis gene in adult patients with asthma. Hum Mutat. 1999;14:510-519.
35. Lowenfels AB, Maisonneuve P, Palys B, Schoni MH, Redemann B. DeltaF508 heterozygosity and asthma. Lancet. 1998;352:985-987.
36. Mennie M, Gilfillan A, Brock DJ, Liston WA. Heterozygotes for the delta F508 cystic fibrosis allele are not protected against bronchial asthma. Nat Med. 1995;1:978-979.
37. Munthe-Kaas MC, Lodrup Carlsen KC, Carlsen KH, et al. CFTR gene mutations and asthma in the Norwegian Environment and Childhood Asthma study. Respir Med. 2006;100:2121-2128.
38. Schroeder SA, Gaughan DM, Swift M. Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis. Nat Med. 1995;1:703-705.
39. Tzetis M, Efthymiadou A, Strofalis S, et al. CFTR gene mutations-including three novel nucleotide substitutions - and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet. 2001; 108:216-221.
40. Holmskov U, Thiel S, Jensenius JC. Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol. 2003;21:547-578.
41. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol. 2003;40:423-429.
42. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis. 2003;37:1496-1505.
43. Nagy A, Kozma GT, Keszei M, Treszl A, Falus A, Szalai C. The development of asthma in children infected with Chlamydia pneumoniae is dependent on the modifying effect of mannose-binding lectin. J Allergy Clin Immunol. 2003;112:729-734.
44. Dahl M, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med. 2004;199:1391-1399.
45. Koch A, Melbye M, Sorensen P, et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA. 2001;285:1316-1321.
46. Demeo DL, Mariani TJ, Lange C, et al. The SERPINE2 Gene Is Associated with Chronic Obstructive Pulmonary Disease. Am J Hum Genet. 2006;78:253-264.
47. Zhu G, Warren L, Aponte J, et al. The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med. 2007;176:167-173.
48. Dahl M, Bowler RP, Juul K, Crapo JD, Levy S, Nordestgaard BG. Superoxide dismutase 3 polymorphism associated with reduced lung function in two large populations. Am J Respir Crit Care Med. 2008;178:906-912.
49. Demeo DL, Hersh CP, Hoffman EA, et al. Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med. 2007;176:42-48.
50. Juul K, Tybjaerg-Hansen A, Marklund S, Lange P, Nordestgaard BG. Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:858-864.
51. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet. 1997;350:630-633.
52. Seifart C, Plagens A. Genetics of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2007;2:541-550.
53. Silverman EK. Progress in chronic obstructive pulmonary disease genetics. Proc Am Thorac Soc. 2006;3:405-408.
54. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1008-1011.
55. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250-255.
56. DiCosmo BF, Geba GP, Picarella D, et al. Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity. J Clin Invest. 1994;94:2028-2035.
57. Hierholzer C, Kalff JC, Omert L, et al. Interleukin-6 production in hemorrhagic shock is accompanied by neutrophil recruitment and lung injury. Am J Physiol. 1998;275:L611-L621.
58. Johnston RA, Schwartzman IN, Flynt L, Shore SA. Role of interleukin-6 in murine airway responses to ozone. Am J Physiol Lung Cell Mol Physiol. 2005;288:L390-L397.
59. Kuhn C III, Homer RJ, Zhu Z, et al. Airway hyperresponsiveness and airway obstruction in transgenic mice. Morphologic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung. Am J Respir Cell Mol Biol. 2000;22:289-295.
60. Park CS, Chung SW, Ki SY, et al. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. Am J Respir Crit Care Med. 2000;162:1162-1168.
61. Romani L, Mencacci A, Cenci E, et al. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med. 1996;183:1345-1355.
62. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6:315-325.
63. Suwa T, Hogg JC, Klut ME, Hards J, van Eeden SF. Interleukin-6 changes deformability of neutrophils and induces their sequestration in the lung. Am J Respir Crit Care Med. 2001;163:970-976.
64. Xing Z, Braciak T, Jordana M, Croitoru K, Graham FL, Gauldie J. Adenovirus-mediated cytokine gene transfer at tissue sites. Overexpression of IL-6 induces lymphocytic hyperplasia in the lung. J Immunol. 1994;153:4059-4069.
65. Yoshida M, Sakuma J, Hayashi S, et al. A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. Proc Natl Acad Sci U S A. 1995;92:9570-9574.
66. Luisetti M, Ma S, Iadarola P, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J. 2008;32:1146-1157.
67. Kobayashi H, Kanoh S, Motoyoshi K. Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical lung damage induced by smoking. Biomarkers. 2008;13:385-392.
68. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:1207-1214.
69. Ohlmeier S, Vuolanto M, Toljamo T, et al. Proteomics of human lung tissue identifiessurfactant protein a as a marker of chronic obstructive pulmonary disease. J Proteome Res. 2008 (in press, available in on-line version).
70. Bhattacharya S, Srisuma S, Demeo DL, et al. Molecular Biomarkers for quantitative and discrete COPD phenotypes. Am J Respir Cell Mol Biol. 2008 (in press, available in on-line version).
71. Larsson K. Inflammatory markers in COPD. Clin Respir J 2008;2:84-87.
72. Snell N, Newbold P. The clinical utility of biomarkers in asthma and COPD. Curr Opin Pharmacol. 2008;8:222-235.